Our society came together in 2014 to focus on the

specific needs of the advanced practitioner. We

are a collaborative group of nurse practitioners,

physician assistants, clinical nurse specialists,

advanced degree nurses, and pharmacists.

We believe an interdisciplinary team approach

to cancer treatment offers the best hope for our

patients’ cure, quality of life, and survivorship.

APSHO.org

What is the Advanced Practitioner Society

for Hematology and Oncology (APSHO)?

2

Our mission is to improve the quality of care for patients with cancer by supporting critical issues in educational, clinical, and professional development for advanced practitioners in hematology/oncology.

What is an AP?

An advanced practitioner is a healthcare professional who has completed advanced training in nursing or pharmacy, or who has completed training as a physician assistant.

...all working in or interested in hematology/oncology, including professionals working in the field of oncology education.

Nurse Practitioners

Clinical Nurse Specialists

Pharmacists

Physician Assistants

Advanced Degree Nurses

Students

IS APSHO FOR ME?Our members are...

3

Membership TypesProfessional memberships are available for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, pharmacists, and physicians working in or interested in hematology/oncology, including professionals working in the field of oncology education.

APSHO also offers associate memberships for healthcare industry professionals and student memberships for those enrolled in an education program leading to eligibility for licensure as an advanced practitioner.

GROUP MEMBERSHIPS

Joining APSHO with your colleagues is easy! Group practices, hospitals, and other organizations can provide their entire staff with APSHO benefits at a reduced group rate. Employers can add, change, or remove employees at any time. Contact memberservices@apsho.org for more information.

Why do we need APs in oncology and hematology?

We have a growing cancer population, a complex set of diseases, and an oncology workforce that is projected to fall short of the expected demand. There are too few oncology providers in practice. To meet the need of the expanding population, efforts for recruitment and retention of oncology providers will be essential.

I think we have to get together as a group and say, “This is who we are, and this is our value to the medical community.”

–APSHO Member

4

BenefitsAPSHO is a society of like-minded professionals devoted to the quality care of patients with cancer. We are the only society dedicated to supporting all oncology advanced practitioners, crucial members of the multidisciplinary healthcare team. We provide the tools to connect, share, and engage with a community of professionals committed to their patients and collaborative teams.

STAY UP TO DATE ON CURRENT ONCOLOGY INFORMATION

Print subscriptions*: APSHO members receive complimentary print subscriptions to the following oncology industry and member publications.

• Journal of the Advanced Practitioner in Oncology (JADPRO)• The quarterly APSHO Advance newsletter• JNCCN—Journal of the National Comprehensive Cancer

Network• The ASCO Post• Journal of Oncology Practice (JOP)*Printed copies mailed to members in the United States only.

ENGAGE AND LEARN WITH EDUCATION CREATED ESPECIALLY FOR YOU

Learn and earn credits live or online: A membership with APSHO allows you to earn CE/CME/CEU credits at the level you need and on your schedule, in-person or on-demand digitally. Members also enjoy discounted registration rates for live events.

• Annual JADPRO LIVE at APSHO conference: Where APSHO’s official journal, JADPRO, comes to life

• JADPRO Regional Lectures: Local, one-day accredited lectures focusing on specific disease states

• Exclusive ability to submit poster abstracts for JADPRO LIVE at APSHO conferences

• 20% savings on tuition for ASCO University: Advanced Practitioner Certificate Programs for Oncology

• Access to the Updates for the Advanced Practitioner series

• APSHO Educator Modules, a resource to educate you and your team using interactive slide decks with comprehensive speaker notes

• APSHO Advanced Practitioner Mentorship Program

CONNECT AND SHARE WITH YOUR COLLEAGUES

Network and career enhancing opportunities just for you: We give you the tools online and in-person to collaborate and grow.

• Special sneak preview of newly posted jobs on the APSHO Career Center

• Practical and empowering career advice from fellow APSHO members in the APSHOempowered video series

• Networking with your peers online through the member portal or in-person at educational events

• Make a difference in the society by helping shape important initiatives and elevating and communicating the value of of the advanced practitioner by serving on an APSHO committee

• Opportunities to contribute to the APSHO Advance Member Newsletter and the Journal of the Advanced Practitioner in Oncology

5

Live National EducationCONFERENCES

JADPRO Live at APSHO conferences are where the Society’s journal, the Journal of the Advanced Practitioner in Oncology (JADPRO), comes to life. The audience for this CE-accredited conference comprises nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and physicians.

JADPRO Live at APSHO conferences offer content at a level specifically geared toward the AP. Conference programming includes workshops, panel discussions, and CE-accredited educational sessions presented throughout the meeting.

The conference allow APs and physicians to come together in a team setting to discuss current treatment options for the patient with cancer, describe key practice initiatives that are essential to the AP, and identify means to improve collaboration—all with an ultimate goal of improving patient outcomes and decreasing symptoms and adverse events.

JADPRO Live at APSHO offers a variety of educational formats:

• Presentations with Q&A

• Interactive case study groups

• Workshops with experts in the field

• Roundtable panel discussions

I’m excited about APSHO because it reflects our multidisciplinary vision.

–APSHO Member

6

JADPRO REGIONAL LECTURE SERIES

Regional lectures focused on a variety of solid tumors and hematologic malignancies are coming to a city near you!

• These accredited activities are half- to full-day educational sessions in various communities around the country.

• Programs provide formalized instruction for APs to supplement on-the-job training that takes place at many oncology practices.

• Registration is discounted for APSHO members. Visit APSHO.org for more information.

Why is APSHO needed?

Our challenge is to fill the educational gaps for all members of the interdisciplinary oncology team. To meet this challenge, we must integrate advances in science and practice while maintaining excellence in care amid changing practice environments. This effort requires lifelong learning and innovative approaches to education. Supporting collaborative practice in oncology care is at the core of the APSHO mission.

7

Online EducationSelect presentations from past JADPRO LIVE at APSHO conferences are available online at APSHO.org. Members have the opportunity to earn credit or contact hours appropriate for their profession.

To learn more about our continuing education offerings, visit the Education section of the APSHO website.

What is collaborative practice?

Collaborative practice implies involvement from all members of the interdisciplinary team. Each person works toward both the best outcome for the patient based on practice guidelines and individualized care. This practice model demands effective working relationships with physicians and other members of the healthcare team.

I’m truly thrilled that APSHO exists. It’s clearly meeting a great need for education, networking, and collaboration for our unique subset of professionals.

–APSHO Member

8

Publications APSHO members receive complimentary subscriptions to the following publications:

Journal of the Advanced Practitioner in OncologyThe mission of JADPRO is to improve the quality of care for patients with cancer, to support critical issues in advanced practice in oncology, and to recognize the expanding contributions of advanced practitioners in oncology. The essential objectives of JADPRO are:

• To publish topics across the cancer trajectory for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists

• To support professional development of the advanced practitioner in oncology

• To promote interprofessional collaboration

• To uphold the highest ethical and professional standards

• To provide information that will enhance the quality of care for the patient with cancer

APSHO Advance The APSHO Advance is our quarterly membership newsletter. This digital publication keeps members informed about society business and happenings, committee updates, and timely news reports of interest to the advanced practitioner. Members are encouraged to contribute to the APSHO Advance.

E� ective Confl ict Resolution Leads to Successful OrganizationsBy Mary E. Peterson, RN, MS, APRN, AOCNP®

Confl ict resolution remains a common theme for business manage-ment lectures. Yet despite the attention given to this topic, it re-mains a diffi cult task for organizations to master. Confl ict can lead

to discord among even the closest of friends and colleagues, but its impact in the corporate setting can be unsettling. The success of businesses relies on the ability of any given organization to rectify confl ict, while ensuring the foundation of its integrity.

Confl ict arises from a very primitive place. Many individuals fail to recognize that we all bring our own biases to the table. And unless all in-dividuals are willing to check their egos at the door, these biases can have long-lasting impact. It’s important to note that ego is distinctively diff erent from individualism and that it is our individuality that leads to construc-tive discussions (Rains, 2011).

INSIDE THIS ISSUE

E� ective Confl ict Resolution Leads to Successful Organizations 1

A Letter From the Editor 3

Preparing the AdvancedPractitioner in Oncology forScientifi c Innovation 10

JADPRO Live 2017Keynote Speaker 11

Practice Metrics 12

Member Profi le 14

Book Corner 17

FDA Update 18

APs in the Literature 21

From the Pages of The ASCO Post 22

Meetings Calendar 31

APSHOAdvanceSUMMER 2017

FEATURE

APSHO.orgContinued on page 8

Pathways

Supportive Care

Toxicities

EmergingTherapies

Targets

PAGE 10

Priming the Pump: Preparing the Advanced

Practitioner in Oncology for Scientifi c Innovation

VOL 8 | NO 6 | SEP/OCT 2017

Original ResearchAssessing the Plain Language Planner for Communication About Common Palliative Care MedicationsElaine Wittenberg, Betty Ferrell, and Joy Goldsmith

ReviewCancer Pain Management: Opioid Analgesics, Part 2Rita J. Wickham

Grand RoundsManaging Drug Interactions in Cancer Therapy:A Guide for the Advanced PractitionerChristopher J. Campen, Wendy H. Vogel, and Pooja J. Shah

Brentuximab Vedotin Infusion Reaction Management: A Case StudyHolly Comer and Kimbra Cardwell

Practice MattersRole of the Advanced Practice Provider inClinical Trials: Contributions to the Managementof Patients Receiving Inotuzumab OzogamicinMary Alma Welch, Joanne C. Ryan, and Ilene Ann Galinsky

Advice About Screening for Prostate Cancer With Prostate-Specifi c AntigenGannel Jean-Pierre

Prescriber’s CornerVenetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic LeukemiaMichelle A. Borg and Amber Clemmons

Tools & TechnologyThe Oncology Care Model forAdvanced PractitionersWendy H. Vogel

advancedpractitioner.com

Official journal of APSHO

9

Journal of the National Comprehensive Cancer NetworkMore than 23,000 oncologists and other cancer care professionals across the United States read JNCCN–Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology®, review articles elaborating on guideline recommendations, health services research, and case reports.

The ASCO PostThe ASCO Post is the clinical news publication most-read by oncology professionals and members of the American Society of Clinical Oncology.

The ASCO Post delivers timely and unbiased reports on major oncology meetings across the globe, including ASCO’s Annual Meeting and regional and thematic symposia. Additionally, The ASCO Post provides readers with important summaries of evidence-based research from peer-reviewed clinical journals (fully sourced with links to original reports); notable research, data, and literature with application in the clinic, including cost considerations/implications; and columns from ASCO’s membership, with perspective on developments in oncology, quality cancer care, technology, electronic medical records, and expert opinion on the state and economics of cancer care.

Journal of Oncology PracticeJournal of Oncology Practice (JOP) provides oncologists and other oncology professionals with key information and insights to enhance practice efficiency and promote a high standard of patient care. JOP presents peer-reviewed original research and perspectives on a variety of issues related to health care delivery. To complement these reports, JOP now publishes clinical reviews, commentaries, and case reports addressing contemporary clinical questions in oncology and rapid areas of change in the field.

James O. Armitage, MDEditor-in-Chief

ASCOPost.com @ASCOPost Send your comments to editor@ASCOPost.com

M O R E I N T H I S I S S U E

L I V E R T R A N S P L A N T offers the highest rates of long-term survival for patients with hepatocellular carcinoma, according to Maria Russell, MD, Assistant Pro-fessor of Surgery at Emory University, Atlanta. At the 2017 Debates and Didactics

in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Russell described the latest trends in liver transplantation.

The other potentially curative option is surgical re-section, and choosing between the two modalities is not always simple. “Patients don’t always fall into nice slots,” she admitted. If both modalities are available to the pa-tient with hepatocellular carcinoma, selection takes into account the degree of cirrhosis, the size and number of lesions, the presence of portal hypertension and comorbid-ities, and insurance/citizenship status.

F O R P AT I E N T S with malignant melanoma, the significant improvement in outcomes with targeted agents and antibodies against the programmed cell death protein 1 (PD-1) has now been observed in the adjuvant setting. Two landmark studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid1,2 have established these drugs as the new standard of care for patients with locally advanced, resectable disease considered at high risk for relapse.

The CheckMate 238 trial showed superiority for nivolumab (Opdivo) over ipilimumab (Yervoy) in reduc-ing the risk of relapse,1 while the COMBI-AD trial revealed “robust” benefits for BRAF/MEK inhibition vs placebo in

BRAF-mutated patients.2 The results of both trials were simultaneously published in The New England Journal of Medicine.3,4

Melanoma experts enthusiastically embraced the findings. Giuseppe Curigliano, MD, PhD, ESMO spokesperson and Associate Professor of Medical Oncology at the University of Milan, opened a press briefing by calling the findings “unprecedented.” Invited discussant Reinhard Dummer, MD, Professor of Dermatology at the University of Zurich in Switzerland, predicted, “The breakthroughs we have heard about will

really change the management of our patients.” “This day, September 11, 2017, will mark a change in our

textbooks and guidelines,” added

V O L U M E 8 | I S S U E 1 8 | S E P T E M B E R 2 5 , 2 0 1 7

Immunotherapyp. 3–5, 52–53

Gynecologic Oncologyp. 9–10

Palliative Care in Cases of Incurable Cancer

p. 37–38

D E R M A T O L O G I C O N C O L O G Y

Significant Improvement in Outcomes Reported With Adjuvant Therapy for Melanoma

b y C A R O L I N E H E L W I C K

S U R G I C A L O N C O L O G Y

Hepatocellular Carcinoma: Current Thoughts on Liver Transplantation

b y C A R O L I N E H E L W I C K

CONTINUED ON P. 11

CONTINUED ON P. 4

ONCOLOGY MEETINGS

ESMO 2017 Congress........................... 3–5

New Orleans Summer Cancer Meeting...................................9–10

Debates and Didactics..11–12, 17–20, 23–24

Prostate Health Education Network.. 80–81

STEVEN E. VOGL, MD, ON DURATION TRIALS .............................. 30–31

PALLIATIVE CARE IN ONCOLOGY......................................... 37–38

TISAGENLECLEUCEL FOR ALL........... 52–53

DIRECT FROM ASCO........................... 54–57

SPECIAL REPORT: CANCER IN RURAL APPALACHIA........................... 91–94

Adoptive Cell Therapy—Act 1: The Beginningb y FREDERICK R. APPELBAUM, MD

“The potential harms associated with the

HPV vaccine are as close to nil as

possible.”b y B A R N E T T S .

K R A M E R , M D , M P H See P. 44

CONTINUED ON P. 110

Maria Russell, MD

Giuseppe Curigliano, MD, PhD

O N A U G U S T 3 0 , 2 0 1 6 , the first genetically engineered T-cell ther-apy (tisagenlecleucel [Kymriah]) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. This approval is a climactic moment in the latest scene of what is turning into an award-winning play: the development of adoptive cell therapy. Where and when did this play begin?

Taking a very broad view, one could go back more than a century to the oft-told story of William Cooley, who, based on observations of rare tumor regression in patients who developed postoperative infections, created a mixture of heat-killed bacteria for intratumoral injec-tions, leading to occasional tumor responses.1

10

When I first transitioned to oncology, my main focus was learning key skills I’d be using in my practice, but I also needed support to guide me through.

–APSHO Member

Committee GoalsEDUCATION COMMITTEE

To build scholarly educational program initiatives aimed at supporting advanced practitioners in oncology at all levels of practice and in varied practice settings.

Primary initiatives will include the annual JADPRO Live at APSHO conference and educational Task Force initiatives (eg, Priming the Pump).

PRIMING THE PUMP TASK FORCE

To prepare the oncology AP workforce for new and cutting-edge diagnostic, therapeutic, and supportive care strategies.

MENTORSHIP TASK FORCE

Created to meet a need our members have expressed for mentoring on the advanced practice level

COMMUNICATIONS COMMITTEE

To provide information about APSHO by facilitating communication between APSHO members and with other associated organizations.

MEMBERSHIP COMMITTEE

To support the society through new member recruitment, existing member retention and occasionally providing input further defining membership and its benefits. .

11

JOIN TODAY!Choose the membership that’s right for you and join APSHO today!

PROFESSIONAL MEMBERSHIP

Individuals who are licensed as nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, pharmacists, and/or physicians working in or interested in hematology/oncology, including professionals working in the field of oncology education.

1 year $75.002 years $120.00

ASSOCIATE MEMBERSHIP

Healthcare industry professionals who do not qualify for Professional Membership as described above.

1 year $200.00

STUDENT MEMBERSHIP

Individuals enrolled in an education program leading to eligibility for licensure as a nurse practitioner, physician assistant, clinical nurse specialist, advanced degree nurse, or pharmacist working in or interested in hematology/oncology, including professionals working in the field of oncology education.

1 year $50.00

INSTITUTION GROUP MEMBERSHIP

Group practices and hospitals that wish to provide their entire staff with APSHO benefits at a reduced group rate. Each employee will have their own website account with a unique username, password and member profile. Employers can add, change or remove employees at any time. Term is for 1 year. Please visit our website for pricing or contact memberservices@apsho.org for more information.

Visit APSHO.org/Join to become a member

www.apsho.org 609-832-3000 info@apsho.org

3131 Princeton Pike Bldg. 1, Suite 205 Lawrenceville, NJ 08648

609-832-3000